Anthony Bergmann Sells 400 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 400 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $30.00, for a total transaction of $12,000.00. Following the sale, the chief financial officer directly owned 11,223 shares of the company’s stock, valued at approximately $336,690. This trade represents a 3.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $15,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00.

Capricor Therapeutics Stock Up 3.0%

Capricor Therapeutics stock opened at $30.40 on Friday. Capricor Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $40.37. The firm has a fifty day moving average of $30.18 and a 200-day moving average of $28.43. The firm has a market capitalization of $1.76 billion, a P/E ratio of -13.10 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, research analysts expect that Capricor Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CAPR has been the topic of several analyst reports. Piper Sandler reiterated an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Roth Mkm reiterated a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a research note on Friday, May 15th. B. Riley Financial upped their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.30.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada boosted its stake in shares of Capricor Therapeutics by 12.4% during the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 557 shares during the last quarter. KBC Group NV acquired a new stake in shares of Capricor Therapeutics during the first quarter worth approximately $44,000. ACT Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter worth $43,000. Nuveen LLC increased its stake in shares of Capricor Therapeutics by 2.1% in the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after buying an additional 1,878 shares during the last quarter. Finally, State of Wyoming raised its holdings in Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 1,913 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.